Clinical Trials
26 trialsAn Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma
Changzhou No.2 People's Hospital
Study of FasT CAR-T GC012F Injection NDMM Patients
Shanghai Changzheng Hospital
the Safety and Efficacy of SENL103 Autologous T Cell Injection
Hebei Senlang Biotechnology Inc., Ltd.
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
First Affiliated Hospital of Fujian Medical University
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
Rutgers, The State University of New Jersey
89Zr-labeled NY008 PET Imaging in Patients
Affiliated Hospital of Jiangnan University
Clinical Study of the Safety and Efficacy of BCMA CAR-NK
Shenzhen Pregene Biopharma Co., Ltd.
A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma
Zhejiang University
Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma
Beijing Immunochina Medical Science & Technology Co., Ltd.
A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
Zhejiang University
68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma
Peking Union Medical College Hospital
Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma
Xinqiao Hospital of Chongqing
BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma
Shanghai Changzheng Hospital
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Hrain Biotechnology Co., Ltd.
BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma
Shanghai Changzheng Hospital
Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma
Xinqiao Hospital of Chongqing
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM
Hebei Yanda Ludaopei Hospital
Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma
Peking Union Medical College Hospital
Treatment of Hematological Malignancy With Novel CAR-T Cells.
Timmune Biotech Inc.
Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
Xijing Hospital
BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma
iCell Gene Therapeutics
BCMA CAR-T
The Pregene (ShenZhen) Biotechnology Company, Ltd.
Study of BCMA CAR-T in Multiple Myeloma
Allife Medical Science and Technology Co., Ltd.
Phase-0-MM
Aalborg University Hospital